Drug Trial Radar · NCT03367195
Efficacy and Safety of DLBS2411 in the Management of GERD
Last checked: Nov 19, 2026Latest source record: Jan 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
32
Actual
Start
Aug 16, 2018
Primary completion
May 4, 2020
Study completion Sep 9, 2020
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, prospective, double-blind double-dummy, randomized-controlled study comparing DLBS2411 at a dose of 250 mg twice daily with omeprazole at a dose of 20 mg twice daily, given before morning and evening meals, for an 8-week course of therapy. Subjects should avoid taking meals 2-3 hours before bedtime. The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. Recent study of DLBS2411 which was conducted in healthy volunteers, demonstrated the effective role and safety of DLBS2411 in suppressing intragastric acidity. Having such mechanisms of action, DLBS2411 is hypothesized to benefit patients with gastric acid disorders such as in gastroesophageal reflux disease (GERD).
Conditions
- Gastroesophageal Reflux Disease (GERD)
Interventions
OmeprazoleDrug
1 Omeprazole 20 mg capsules twice daily
DLBS2411Drug
1 DLBS2411 caplet 250 mg, twice daily
Placebo capsule of OmeprazoleDrug
1 placebo capsule of omeprazole, twice daily
Placebo caplet of DLBS2411Drug
1 placebo caplet of DLBS2411, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Healing rate by endoscopyTime frame: 8 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Padjajaran Dr. Hasan Sadikin Hospital
Bandung, Indonesia
Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital
Jakarta, Indonesia
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Diponegoro Dr. Kariadi Hospital
Semarang, Indonesia
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Airlangga Dr. Soetomo Hospital
Surabaya, Indonesia
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Gadjah Mada Dr. Sardjito Hospital
Yogyakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.